He didn't want to say this, but IMO, a partnership for ROW for QNEXA is worth an awful lot of money with a big initial investment. An upfront payment of $250-500 million would go a long way towards a sales force in the US. Too many positives. If approved, VVUS won't remain independent for that long. Easier to buy whole company than to do a ROW QNEXA deal and/or ED drug deal.
CEO is smart, saying he wants to wait for FDA approval, stock should be $50-$70 by then, then he can be opportunistic and raise money with less stock, so as to not hurt or dilute current owners. He is as he says OPPORTUNISTIC!
my take was ceo was urging investors to be responsible. i interpreted he doesnt want the investment community to think this is going to be a drug that will be marketed to everybody. sounded to me like he will do a secondary. i sold my long position. i will not short however. it could keep going. imo, the easy money has been made. going back to ktcc now.
Ask yourself, would you start spending cash on an marketing campaign prior to approval. I think not. Cardiovascular study post approval is a plus not a minus. It will be part of the marketing campaign. Opportunistic in raising cash means retaining US rights and engaging an overseas partner. JMHO
if it was dilute. the stock only has 88m shares. it is extremely volatile with that few shares. It will create stability and more money for the company if he does. This time.. Id be for it.